Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention

American Journal of Health-System Pharmacy

Volumn 67, Issue 15 SUPPL. 7, 2010, Pages

  Roffman, David S ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Acute coronary syndrome; Angioplasty; Clopidogrel; Coronary thrombosis; Drug interactions; Pharmacogenetics; Platelet aggregation inhibitors; Stents; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; OMEPRAZOLE; PACLITAXEL; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; INTRACORONARY THROMBOSIS; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESTENOSIS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; CORONARY ARTERY THROMBOSIS; DRUG ADMINISTRATION; GENETICS; ORAL DRUG ADMINISTRATION; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON, CORONARY; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 79551643481     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100166     Document Type: Conference Paper

References (31)

1. Malenka DJ, Kaplan AV, Lucas FL et al. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA. 2008; 299:2868-76. (Pubitemid 351930886)
2. James SK, Stenestrand U, Lindback J et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 2009; 360:1933-45.
3. Frobert O, Lagerqvist B, Carlsson J et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol. 2009; 53:1660-7.
4. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293:2126-30. (Pubitemid 40617065)
5. Schomig A. Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med. 2009; 361:1108-11.
6. Gilard M, Arnaud B, Cornily JC et al. In fluence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51:256-60.
7. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360:354-62.
8. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119:2553-60.
9. Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116:2923-32. (Pubitemid 350291199)
10. Serebruany VL, Steinhubl SR, Berger PB et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45:246-51. (Pubitemid 40094733)
11. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49:1505-16. (Pubitemid 46517957)
12. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006; 48:1742-50. (Pubitemid 44648629)
13. Frelinger AL III, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005; 46:646-7. (Pubitemid 41132691)
14. Labarthe B, Theroux P, Angioi M et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol. 2005; 46:638-45. (Pubitemid 41132690)
15. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001; 12:443-7. (Pubitemid 33097240)
16. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005; 3:85-92. (Pubitemid 41647119)
17. Kleiman NS. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel? J Am Coll Cardiol. 2008; 51:1412-4.
18. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008; 51:1404-11. (Pubitemid 351447314)
19. Accumetrics. VerifyNow P2Y12 test. www.accumetrics.com/products/vnp2y12. aspx (accessed 2010 Feb 5).
20. ClinicalTrials.gov. GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety. www.clinicaltrials.gov/ct2/show/ NCT00645918 (accessed 2010 Feb 4).
21. Gurbel PA, Bliden KP, Hayes KM et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005; 45:1392-6. (Pubitemid 40615608)
22. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:66.e9-16.
23. Plavix (clopidogrel bisulfate) tablets package insert. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2010 Mar.
24. Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51:1925-34. (Pubitemid 351636443)
25. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302:849-57.
26. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118:1894-909.
27. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44.
28. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374:989-97.
29. Bhatt DL. The COGENT trial. Latebreaking clinical trials II. Paper presented at Transcatheter Cardiovascular Therapeutics Meeting. San Francisco, CA; 2009 Sept 24.
30. Food and Drug Administration. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as prilosec and prilosec OTC). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHealthcareProfessionals/ucm190787.htm (accessed 2010 Feb 6).
31. Hughes S. Cardiologists shocked by new FDA alert on clopidogrel-PPI interaction. www.theheart.org/article/1025121.do (accessed 2010 Feb 6).